Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Radiotherapy Combined With Capecitabine and Sorafenib in Patients With Advanced, K-ras Mutated Rectal Cancer. A Multicenter Phase I/IIa Trial.

NCT00869570 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00869570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00869570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Radiotherapy Combined With Capecitabine and Sorafenib in Patients With Advanced, K-ras Mutated Rectal Cancer. A Multicenter Phase I/IIa Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2009
Completion date
September 30, 2016
Enrollment
54 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer